title: [Observational survey of the French Urological Association evaluating intermittent hormonal modalities treatment in prostate cancer in France].
abstract: OBJECTIVE
  To assess clinical practice of intermittent hormone therapy (IHT) among urologists members of the French Association of Urology.
  
  
  METHODS
  Internet-based observational survey evaluating IHT modalities in prostate cancer using questionnaire sent to 941 urologists.
  
  
  RESULTS
  Two hundred and sixty nine urologists participated in the survey (response rate 28.6 %) including 90.3 % prescribing IHT. The main reasons for IHT were improvement of quality of life in 94.2 %, clinical tolerance in 73.7 %, decreased costs and oncological equivalence in 44 %. The indications were localized prostate cancer (low risk 22.6 %, intermediate 19.8 %, high 14 %), locally advanced (59.7 %), metastatic (63.4 %), biochemical recurrence after local treatment (prostatectomy 62.1 %, radiotherapy 73.7 %). A PSA <2 ng/mL was considered as the threshold for androgen deprivation therapy break in 70 % of cases regardless of the IHT indication. The PSA threshold selected for the re-initiation of treatment was 4 ng/mL in 37.9 % and 10 ng/mL in 36.6 % of cases. The cycle of IHT was 6 months in 60 % of cases.
  
  
  CONCLUSIONS
  This survey provided a snapshot of the practice of IHT in France. Even in the absence of level of evidence 1 trials in the literature, most urologists used IHT in their clinical practice, for many indications, especially in case of biochemical recurrence after local treatment.
  
  
  METHODS
  3.
authors.affiliation: CHU Henri-Mondor, 51, avenue du Maréchal-de-Tassigny, 94010 Créteil, France. Electronic address: laurent.salomon@hmn.aphp.fr.
authors.forename: L
authors.initials: L
authors.lastname: Salomon
authors.affiliation: CHU Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Ploussard
authors.affiliation: Centre hospitalier René Dubos, 6, avenue de l'Ile-de-France, 95300 Pontoise, France.
authors.forename: P
authors.initials: P
authors.lastname: Coloby
authors.affiliation: Centre hospitalier Périgueux, 80, avenue Georges-Pompidou, 24019 Périgueux cedex, France.
authors.forename: G
authors.initials: G
authors.lastname: Kouri
authors.affiliation: Hôpital Foch, 40, rue Worth, 92151 Suresnes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.affiliation: HEGP, 20, rue Leblanc, 75015 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Méjean
authors.affiliation: Clinique Pasteur, 222, route de Rochefort, 17200 Royan, France.
authors.forename: D
authors.initials: D
authors.lastname: Prunet
authors.affiliation: CHU Rangueil, 1, avenue du Pr Jean Poulhès, TSA 50032, 31059 Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Soulié
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000191:economics / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000191:economics / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D004334:Drug Administration Schedule; D005602:France; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000191:economics / Q000628:therapy; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014572:Urology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
keywords: Cancer de la prostate; Intermittent hormonal treatment; Outcomes; Prostate cancer; Quality of life; Qualité de vie; Résultats; Traitement hormonal intermittent